About This Calculator
The Dupilumab Dose Calculator is a clinical support tool designed to determine the appropriate initiation and maintenance dosing schedule for Dupilumab (Dupixent®). It bases its calculations on the patient's specific indication, age, and body weight, aligning with the FDA-approved prescribing information.
Understanding the Outputs
After entering the required patient data, the calculator provides a clear, concise dosing recommendation, which includes:
- Loading Dose: The initial higher dose required for certain indications to rapidly achieve therapeutic levels.
- Maintenance Dose: The regular, ongoing dose amount and frequency.
- Administration Details: The dose specified in milligrams (mg) and the corresponding number of subcutaneous injections required per administration.
- Indication-Specific Notes: Important context, such as the absence of a loading dose for certain pediatric populations or indications.
How to Use the Calculator
To use the calculator effectively, follow these steps:
- Select Indication: Choose the patient's condition from the dropdown menu (e.g., Atopic Dermatitis, Asthma).
- Enter Patient Age: Input the patient's age in years and months. This field is only required for indications where age is a dosing factor.
- Enter Patient Weight: Provide the patient's body weight and select the unit (kg or lbs). This is also only required for weight-based dosing regimens.
- Specify Asthma Phenotype (if applicable): For patients aged 12 and older with asthma, check the box if they have oral corticosteroid-dependent asthma or comorbid moderate-to-severe atopic dermatitis, as this affects the recommended dose.
Dosing Overview
Dupilumab dosing is highly specific to the indication and patient characteristics:
- Atopic Dermatitis: Dosing varies significantly across age groups (adults, adolescents 12-17, children 6-11, and young children 6 months-5 years) and is often dependent on weight-based tiers within these groups.
- Asthma: For patients 12 years and older, two primary dosing regimens exist based on whether the patient has an OCS-dependent phenotype or comorbid atopic dermatitis. For children 6-11 years, dosing is based on body weight.
- CRSwNP & Prurigo Nodularis: These indications in adults typically follow a standard dosing regimen consisting of a loading dose followed by a fixed maintenance dose every two weeks.
- Eosinophilic Esophagitis: In patients 12 years and older weighing at least 40 kg, this is the only indication requiring a weekly maintenance dose, without a loading dose.
Switching Therapies
When transitioning a patient to Dupilumab from another biologic agent, there is no specific mandated washout period. The decision to initiate Dupilumab should be based on clinical judgment, considering the pharmacokinetics (e.g., half-life) and mechanism of action of the previous therapy. Always consult the full prescribing information for both agents.
Missed Dose Instructions
Guidance for a missed dose depends on the prescribed administration schedule:
- For every 2 weeks or every 4 weeks dosing: If a dose is missed, instruct the patient to administer the injection as soon as possible, then resume the original schedule from the date of the most recent injection.
- For weekly dosing (EoE): If a dose is missed, the patient should administer it as soon as possible and then resume the weekly schedule beginning from that new date.
Patients should not administer two doses at once to make up for a missed dose.
Safety Alerts
This calculator is not a substitute for clinical judgment and the full prescribing information. Key safety considerations for Dupilumab include hypersensitivity reactions, conjunctivitis and keratitis, eosinophilic conditions, and arthralgia. Co-administration of live vaccines should be avoided. Refer to the full Prescribing Information for a complete list of warnings, precautions, and adverse events before initiating therapy.
Frequently Asked Questions (FAQ)
Why does the calculator require age and weight for some indications but not others?
Dosing for Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis is approved for specific age and/or weight-based cohorts. Indications like CRSwNP and Prurigo Nodularis are currently approved for adults (18+) with a standard dose, making age and weight inputs unnecessary for the calculation.
Why is there a special checkbox for asthma patients?
For patients aged 12 and older with asthma, the recommended initial dosing differs. A higher loading dose (600mg) and maintenance dose (300mg every 2 weeks) is recommended for those with oral corticosteroid-dependent asthma or comorbid moderate-to-severe atopic dermatitis.
Does the calculator provide dosing for off-label uses?
No. This tool calculates doses strictly based on the FDA-approved indications, age groups, and weight criteria as listed in the official prescribing information.
Why is there no loading dose for pediatric asthma or CRSwNP?
The clinical trials that established the safety and efficacy for these specific populations and indications did not include a loading dose. The recommended regimen is designed to achieve therapeutic effect without one.
How should I proceed if a patient's weight crosses a dosing threshold during treatment?
The prescribing information does not provide specific guidance on dose adjustments for patients who cross a weight threshold post-initiation. This decision should be based on clinical judgment, considering the patient's therapeutic response and tolerance.
What happens if I enter an age or weight outside the approved range?
The calculator will display an error message indicating that Dupilumab is not approved for that demographic for the selected indication, prompting you to consult the official prescribing information.
Does the calculator account for renal or hepatic impairment?
No. No dose adjustments are recommended for patients with renal or hepatic impairment in the official prescribing information. The calculator does not adjust for these conditions.
Where can I find the most current prescribing information?
The most up-to-date information can always be found on the manufacturer's website or via the FDA's Drugs@FDA database (see references below).
References
- DUPIXENT® (dupilumab) Prescribing Information. Regeneron Pharmaceuticals, Inc. / Sanofi.
- Dupixent EPAR Product Information. European Medicines Agency.
- Official Dupixent Healthcare Professional Website. Sanofi & Regeneron Pharmaceuticals, Inc.
- FDA Drugs@FDA Database. U.S. Food & Drug Administration.
